Huadong Medicine’s oral GLP-1 drug HDM1002 meets all Phase III weight-loss endpoints, NDA planned in China
Huadong Medicine announced on September 27 that its oral GLP-1 receptor agonist HDM1002 met all primary and key secondary endpoints in a Phase III trial for weight management in overweight or obese adults in China. At week 44, 200mg and 400mg doses achieved average weight reductions of 9.2% and 10.7% versus 1.5% for placebo, with continued loss through week 52. The company has completed pre-NDA communication and will soon submit a marketing application in China.
Reference imageEditorial responsibility
- No named human review is recorded for this page.
- Reports are grouped by semantic similarity and deterministic rules. Language models may assist titles, summaries, translation and cross-source analysis; the page reads the event directly, while its address stays stable when the title changes.
- Summary covers the current reports
Cross-source coverage
Common ground
- Huadong Medicine's HDM1002 is a positive development for Chinese biopharma innovation.
- Food-independent absorption is a real-world advantage for patient convenience.
- The 'no plateau' weight loss signal at 52 weeks is worth further investigation.
- Huadong's existing commercial infrastructure in China is a genuine asset for market entry.
- The drug's success depends on commercialization, pricing, and real-world adherence.
Points of contention
- Eastern Agent sees HDM1002 as a strategic breakthrough and sign of Chinese sovereignty, while Neutral Agent views it as an incremental step in a crowded field.
- Eastern Agent argues 12.2% weight loss with no plateau is superior to orforglipron's 14.7% at 36 weeks, but Neutral Agent says the comparison is flawed without head-to-head data.
- Eastern Agent calls HDM1002 'first-in-class' for Chinese oral GLP-1s, while Neutral Agent says it's a 'fast follower' in a well-established mechanism.
- Eastern Agent emphasizes geopolitical and supply chain independence, while Neutral Agent focuses on technical metrics and market realities.
- Neutral Agent warns of pricing traps and regulatory risks, which Eastern Agent downplays as manageable.
Blind spots
- Both sides overlook the potential impact of patient dropout rates and long-term tolerability on real-world use.
- The debate lacks discussion of how HDM1002 might perform in non-Chinese populations or global markets.
- Neither agent addresses the environmental or ethical implications of mass-producing GLP-1 drugs for obesity.
- The role of patient education and lifestyle support in maximizing drug efficacy is not considered.
WorldAttention’s read
Huadong Medicine's HDM1002 is a promising oral GLP-1 drug with a differentiated profile, including food-independent absorption and a non-plateauing weight loss curve at 52 weeks. While Eastern Agent frames it as a strategic victory for Chinese pharmaceutical sovereignty, Neutral Agent rightly cautions that it is an incremental advance in a competitive field, not a revolution. Both agree that commercialization, pricing, and real-world adherence will determine its true impact. The drug's success hinges on Huadong's ability to leverage its domestic infrastructure, navigate China's pricing system, and prove long-term efficacy and safety beyond press releases. Ultimately, HDM1002 is a solid achievement worth watching, but it is not yet a paradigm shift.
Reporting timeline
Huadong Medicine's Oral GLP-1 Drug Shows Positive Phase III Weight Loss Results, NDA Planned
Huadong Medicine (000963.SZ) announced on September 27 that its wholly-owned subsidiary, Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., has achieved positive top-line results from a Phase III clinical study (HDM1002-301) in China for its oral small-molecule GLP-1 receptor agonist, HDM1002 (Conveglipron Trometamol Tablets), for weight management in overweight or obese individuals. The study showed that all dose groups met all primary and key secondary endpoints at week 44, with continued weight loss through week 52 and no observed plateau. The drug also demonstrated significant improvements in multiple cardiometabolic parameters, substantial reductions in liver fat content, and favorable body composition changes. Safety and tolerability were consistent with the GLP-1 receptor agonist class, with no new safety signals. The company has completed Pre-NDA communication and will soon formally submit a New Drug Application in China for the weight management indication.
Read sourceHuadong Medicine's Oral GLP-1 Agonist HDM1002 Shows Positive Phase III Weight Loss Results
Huadong Medicine (000963) announced on September 27 that its wholly-owned subsidiary, Zhongmei Huadong, achieved positive top-line results from the China Phase III clinical study (HDM1002-301) of its oral small-molecule GLP-1 receptor agonist HDM1002 for weight management in overweight or obese individuals. The study showed that all dose groups met all primary and key secondary endpoints at week 44, with continued weight loss through week 52 and no observed plateau. The drug also demonstrated significant improvements in multiple cardiometabolic parameters, substantial reductions in liver fat content, and optimized body composition. Safety and tolerability were consistent with the GLP-1 receptor agonist class, with no new safety signals. The company has completed pre-NDA communication and will soon submit a marketing application in China for HDM1002 for weight management.
Read sourceHuadong Medicine's Oral GLP-1 Drug HDM1002 Shows Positive Weight Loss Phase III Results
Huadong Medicine (000963.SZ) announced that its wholly-owned subsidiary, Zhongmei Huadong, has achieved positive top-line results from a Phase III clinical study (HDM1002-301) in China for its oral small-molecule GLP-1 receptor agonist, HDM1002, for weight management in overweight or obese individuals. The study showed that all dose groups met all primary and key secondary endpoints at week 44, with continued weight loss through week 52 and no observed plateau. The drug also demonstrated significant improvements in multiple cardiometabolic markers, substantial reductions in liver fat content, and favorable body composition changes. Safety and tolerability were consistent with the GLP-1 receptor agonist class, with no new safety signals. The company has completed a Pre-NDA communication and will soon submit a marketing application in China for HDM1002 for weight management.
Read sourceShow 2 older updatesHide older updates
Huadong Medicine's Oral GLP-1 Drug HDM1002 Meets Phase III Weight Loss Endpoints
Huadong Medicine (华东医药) announced on September 27 that its self-developed oral small-molecule GLP-1 receptor agonist, HDM1002, met all primary and key secondary endpoints in a Phase III clinical trial for weight management. The 52-week study enrolled 857 obese or overweight adults. At week 44, the 200mg and 400mg daily doses led to average weight reductions of 9.2% and 10.7%, respectively, versus 1.5% for placebo. By week 52, reductions reached 10.7% and 12.2%. The drug showed a 'fat-reducing, muscle-sparing' profile and improvements in cardiometabolic markers and liver health. Huadong Medicine has completed a pre-NDA meeting and will soon file for marketing approval in China. The company positions HDM1002 as a convenient oral alternative to injectable GLP-1 drugs, aiming to improve patient compliance. It is also advancing other pipeline candidates, including HDM1005 (GLP-1R/GIPR dual agonist) and DR10624 (triple agonist), targeting different metabolic indications.
Huadong Medicine's Oral GLP-1 Agonist HDM1002 Shows Positive Phase III Weight Loss Results
Huadong Medicine (000963) announced on September 27 that its wholly-owned subsidiary, Zhongmei Huadong, achieved positive top-line results from the Phase III clinical study (HDM1002-301) of its oral small-molecule GLP-1 receptor agonist HDM1002 for weight management in overweight or obese adults in China. The study showed that all dose groups met all primary and key secondary endpoints at week 44, with continued weight reduction through week 52 and no observed weight-loss plateau. The drug also demonstrated significant improvements in multiple cardiometabolic markers, substantial reduction in liver fat content, and favorable body composition changes. Safety and tolerability were consistent with the GLP-1 receptor agonist class, with no new safety signals. The company has completed pre-NDA communication and will soon submit a marketing application in China for the weight management indication.
Read source